BRIEF published on 12/11/2025 at 23:05, 6 months 12 days ago Xenetic Biosciences ajourne son assemblée générale annuelle des actionnaires de 2025. Instructions De Vote Quorum Biosciences Xénétiques Assemblée Générale Des Actionnaires Ajournement De 2025
BRIEF published on 12/11/2025 at 23:05, 6 months 12 days ago Xenetic Biosciences Adjourns 2025 Annual Stockholders Meeting Xenetic Biosciences Stockholders Meeting Voting Instructions Quorum 2025 Adjournment
PRESS RELEASE published on 12/11/2025 at 23:00, 6 months 12 days ago Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting Xenetic Biosciences, Inc. adjourns 2025 Annual Meeting of Stockholders due to lack of quorum. Stockholders urged to vote before reconvened meeting on January 8, 2026 Xenetic Biosciences Stockholders Quorum Proxy Vote 2025 Annual Meeting
BRIEF published on 11/19/2025 at 14:50, 7 months 5 days ago Xenetic Biosciences étend sa collaboration avec Scripps Research Biopharmaceutique Traitement Du Cancer DNase I Thérapie CAR-T Recherche Scripps
BRIEF published on 11/19/2025 at 14:50, 7 months 5 days ago Xenetic Biosciences Extends Collaboration with Scripps Research Cancer Treatment Biopharmaceutical DNase I CAR-T Therapy Scripps Research
PRESS RELEASE published on 11/19/2025 at 14:45, 7 months 5 days ago Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator at Scripps Research to Advance DNase Platform Xenetic Biosciences extends collaboration with Scripps Research to advance DNase-based immuno-oncology treatment for cancers Xenetic Biosciences Immuno-oncology DNase I CAR-T Therapy Scripps Research
BRIEF published on 11/13/2025 at 14:50, 7 months 11 days ago Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2025 Résultats Financiers Essais Cliniques Augmentation Des Revenus Technologie DNase Carcinome Pancréatique
BRIEF published on 11/13/2025 at 14:50, 7 months 11 days ago Xenetic Biosciences Reports Q3 2025 Financial Results Financial Results Revenue Increase Clinical Trials Pancreatic Carcinoma DNase Technology
PRESS RELEASE published on 11/13/2025 at 14:45, 7 months 11 days ago Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results Xenetic Biosciences, Inc. reports Q3 2025 financial results, focuses on DNase-based technology for cancer treatment. Secured $3.9 million from offering, advancing collaborations Xenetic Biosciences Cancer Treatment Collaborations DNase Technology Q3 2025 Financial Results
BRIEF published on 10/10/2025 at 15:35, 8 months 14 days ago Xenetic Biosciences Announces $4.5 Million Stock Offering Xenetic Biosciences Biopharmaceutical Immuno-oncology Stock Offering Canaccord Genuity
Published on 06/24/2026 at 14:45, 3 hours 16 minutes ago Amdocs Selected by Three Scandinavia to Support Customer Engagement Transformation Across Nordic Markets
Published on 06/24/2026 at 14:00, 4 hours 1 minute ago GameSquare and U.S. Army Partner for Soldier Showdown 8, Presented by USAA
Published on 06/24/2026 at 14:00, 4 hours 1 minute ago Adcore Announces Voting Results from Annual Shareholders Meeting
Published on 06/24/2026 at 13:05, 4 hours 56 minutes ago Faraday Copper Reports Drill Results Including Near-Surface Copper Mineralization in the American Eagle Area
Published on 06/24/2026 at 17:46, 14 minutes ago GESCO AGM 2026: Proposed resolutions passed by a large majority
Published on 06/24/2026 at 17:40, 21 minutes ago BROADPEAK SA: Descriptif du programme de rachat d’actions propres approuvé par l’assemblée générale du 23 juin 2026
Published on 06/24/2026 at 17:20, 41 minutes ago AL-S Pharma Presents AP-101 Phase 2 Data Supporting Misfolded SOD1 as a Therapeutic Target in ALS at ENCALS 2026
Published on 06/24/2026 at 17:45, 16 minutes ago Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno
Published on 06/24/2026 at 17:45, 16 minutes ago Air Liquide continues its long-term growth in Kazakhstan with a key investment to support Silleno's world-scale plant
